A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix

Trial Profile

A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2018

At a glance

  • Drugs Axalimogene filolisbac (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Feb 2018 According to an Advaxis media release, based on the 12-month survival rates observed in this trial, the company has submitted a conditional Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for axalimogene filolisbac, for the treatment of adult women who progress beyond first-line therapy of persistent, recurrent or metastatic carcinoma of the cervix (PRmCC).
    • 12 Feb 2018 According to an Advaxis media release, data from this study will support upcoming planned submission of a conditional Marketing Authorization Application with the European Medicines Agency for axalimogene filolisbac for the treatment for metastatic cervical cancer.
    • 01 Aug 2017 Status changed from suspended to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top